The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It's a pity that we got cornered with this POS, could have invested in IMM Immupharma about the same time ten years ago at 20p now trading at 150p. Scott and his theories about Nasdaq listing got us nothing but dilution and wasted opportunities.
Who was England's first chiropodist? William the Corncurer
doesn't seem to work. Anyway, in the Disclosure section, Ghenkin, Lockshin and our Prof Gregoriades are mentioned - familiar XBIO names.
The Disclosure here is interesting; several familiar names: https://link.springer.com/article/10.1007/s13311-016-0448-0. Not sure what we can read into it though.
The Disclosure here is interesting; several familiar names: https://link.springer.com/article/10.1007/s13311-016-0448-0. Not sure what we can read into it though.
Is this the goose that laid the golden egg. Nothing on it for over a year https://multiplesclerosisnewstoday.com/2016/06/30/new-MS-vaccine-soon-to-enter-phase-3-testing/
It's either nearly worthless, as the share price would have us believe, or it's grossly undervalued, as the minuscule volume being churned every day in the absence of meaningful news might indicate. In any event, at little over two dollars, what's the point of selling? May as well either go bust with it or take a punt on something actually working, by a miracle.
No info on what polyxen is being attached to and when. Then the price being held at this ridiculous level even though we are ok for cash and running trials. So only thing I can see is the board are still to give themselves loads more freebies. Nightmare share. Instead of being 36 dollars these people are cleaning is out at 2 dollars
graceful.
Every day,a male employee walks up very close to a female co-worker at the coffee machine. He stops,inhales quite deeply and says that her hair smells very nice. After a week of this,the woman can�t stand it anymore. She takes her issue to a supervisor in Human Resources and ask to file a sexual harassment grievance against the guy. The supervisor is puzzled and asks:�What�s threatening about a co-worker telling you that your hair smells nice?� �It�s Frank the midget.
Directors busy lining their pockets with cheap options. Hopefully we get some scraps if ever the price moves upwards. Sigh
It's the wonderful world of XBIO, where things appear and disappear with no apparent rhyme or reason. How we ended up in slavery to this recurring nightmare I'll never know.
EPO also seems to have vaporised. Another mirage or just on hold?
It was a virtual AGM. Virtually non-existent except as a mirage that recedes as you approach it.
There has been no official AGM announcement
has bounced back to 2.23
well, read this then ... http://www.businesswire.com/news/home/20171115005234/en/Xenetic-Biosciences-Reports-2017-Quarter-Financial-Results
Nothing about the AGM on that.....
I cant find anything. Send a link
Unless we go beyond 50 million MC soon, mintaining Nasdaq listing is questionable. What rabbit will they pull out this time to finance beyond 2nd quarter 2018. Delisting??????hope not
Check out the website for the AGM info. With the 7 million gained in November the company con continue to Q2 2018. The SP took a dive after the AGM and financial results.
how was it? did anyone here attend?
Not the most interesting quarterly report published.
lets hope it happens this time round